Table 1 Patient characteristics at study entry
From: Abnormal body composition, cardiovascular endurance, and muscle strength in pediatric SLE
Characteristic | Value |
|---|---|
Age, mean (SD) | 15.5 (3.1) |
Female gender, n (%) | 9 (90 %) |
African American, n (%) | 8 (80 %) |
Mean years with SLE, (SD) | 4.2 (2.3) |
Malar rash, n (%) | 6 (60 %) |
Kidney disease, n (%) | 5 (50 %) |
Focal proliferative, n (%) | 1 (10 %) |
Membranous, n (%) | 1 (10 %) |
Diffuse proliferative, n (%) | 3 (30 %) |
ANA positive, n (%) | 10 (100 %) |
dsDNA positive, n (%) | 9 (90 %) |
Ro/La positive, n (%) | 2 (20 %) |
Smith positive, n (%) | 3 (30 %) |
Low C3/C4, n (%) | 2 (20 %) |
Elevated ESR/CRP, n (%) | 0 (0 %) |
Anemia, n (%) | 0 (0 %) |
Prednisone | 4 (40 %) |
Dose | 0.1–0.5 mg/kg/day |
Duration, mean months, (SD) | 2 (3.1) |
Hydroxychloroquine, n (%) | 10 (100 %) |
Methotrexate, n (%) | 2 (20 %) |
Mycophenolate mofetil, n (%) | 4 (40 %) |